Exagen (XGN) Competitors $6.86 +0.03 (+0.44%) As of 11:00 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XGN vs. CSTL, PSNL, INNV, EHAB, SBC, CELC, AUNA, TALK, OMDA, and FTREShould you be buying Exagen stock or one of its competitors? The main competitors of Exagen include Castle Biosciences (CSTL), Personalis (PSNL), InnovAge (INNV), Enhabit (EHAB), SBC Medical Group (SBC), Celcuity (CELC), Auna (AUNA), Talkspace (TALK), Omada Health (OMDA), and Fortrea (FTRE). These companies are all part of the "healthcare" industry. Exagen vs. Its Competitors Castle Biosciences Personalis InnovAge Enhabit SBC Medical Group Celcuity Auna Talkspace Omada Health Fortrea Exagen (NASDAQ:XGN) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment. Do institutionals & insiders believe in XGN or CSTL? 75.3% of Exagen shares are owned by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are owned by institutional investors. 12.6% of Exagen shares are owned by company insiders. Comparatively, 6.5% of Castle Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has preferable earnings & valuation, XGN or CSTL? Castle Biosciences has higher revenue and earnings than Exagen. Castle Biosciences is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExagen$55.64M2.63-$15.11M-$0.84-8.17Castle Biosciences$347.08M1.68$18.25M-$0.19-106.05 Does the media refer more to XGN or CSTL? In the previous week, Castle Biosciences had 2 more articles in the media than Exagen. MarketBeat recorded 2 mentions for Castle Biosciences and 0 mentions for Exagen. Castle Biosciences' average media sentiment score of 1.70 beat Exagen's score of 0.00 indicating that Castle Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Exagen Neutral Castle Biosciences Very Positive Which has more risk & volatility, XGN or CSTL? Exagen has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Comparatively, Castle Biosciences has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Do analysts rate XGN or CSTL? Exagen presently has a consensus price target of $7.50, indicating a potential upside of 9.33%. Castle Biosciences has a consensus price target of $37.00, indicating a potential upside of 83.63%. Given Castle Biosciences' higher possible upside, analysts plainly believe Castle Biosciences is more favorable than Exagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exagen 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Castle Biosciences 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is XGN or CSTL more profitable? Castle Biosciences has a net margin of -1.46% compared to Exagen's net margin of -27.34%. Castle Biosciences' return on equity of 3.41% beat Exagen's return on equity.Company Net Margins Return on Equity Return on Assets Exagen-27.34% -133.69% -34.87% Castle Biosciences -1.46%3.41%2.95% SummaryCastle Biosciences beats Exagen on 11 of the 15 factors compared between the two stocks. Get Exagen News Delivered to You Automatically Sign up to receive the latest news and ratings for XGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XGN vs. The Competition Export to ExcelMetricExagenMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$146.12M$10.54B$5.59B$8.99BDividend YieldN/A2.09%5.25%4.03%P/E Ratio-8.1716.5927.5420.13Price / Sales2.6331.46415.83172.83Price / CashN/A22.7937.0657.97Price / Book12.703.768.105.61Net Income-$15.11M$235.43M$3.17B$248.50M7 Day Performance1.86%3.69%3.33%4.36%1 Month Performance-6.79%3.98%3.54%6.87%1 Year Performance268.82%-10.14%33.62%20.78% Exagen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XGNExagen3.6462 of 5 stars$6.86+0.4%$7.50+9.3%+261.4%$146.12M$55.64M-8.17220CSTLCastle Biosciences3.0331 of 5 stars$20.42+0.3%$37.00+81.2%+12.7%$587.55M$332.07M-107.47540Positive NewsPSNLPersonalis3.5106 of 5 stars$6.56-0.3%$7.67+16.9%+380.5%$581.18M$85.69M-5.09400News CoveragePositive NewsINNVInnovAge0.8805 of 5 stars$3.69-5.9%$5.00+35.5%-17.7%$529.25M$763.85M-16.042,350EHABEnhabit2.7269 of 5 stars$9.64+0.8%$8.75-9.2%-17.3%$484.09M$1.03B-3.4810,700News CoveragePositive NewsSBCSBC Medical GroupN/A$4.64flatN/AN/A$480.76M$205.42M0.00N/AHigh Trading VolumeCELCCelcuity1.9868 of 5 stars$13.35+6.5%$30.80+130.7%-21.1%$474.84MN/A-4.4140AUNAAuna3.3157 of 5 stars$6.20-2.2%$10.70+72.6%-19.4%$469.24M$1.17B10.6914,842High Trading VolumeTALKTalkspace3.9464 of 5 stars$2.78+0.4%$4.50+61.9%+29.3%$463.46M$187.59M139.07500Positive NewsOMDAOmada HealthN/A$18.30+3.9%N/AN/A$453.46MN/A0.00849Analyst ForecastFTREFortrea3.8828 of 5 stars$4.94-0.8%$15.00+203.6%-78.3%$450.69M$2.70B-0.5615,500Analyst Forecast Related Companies and Tools Related Companies CSTL Alternatives PSNL Alternatives INNV Alternatives EHAB Alternatives SBC Alternatives CELC Alternatives AUNA Alternatives TALK Alternatives OMDA Alternatives FTRE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XGN) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.